Clinical Study
Safety and Efficacy of Stereotactic Body Radiation Therapy in the Treatment of Pulmonary Metastases from High Grade Sarcoma
Table 1
Patient and tumor characteristics.
| Age at time of treatment (years) | | Median | 56 | Range | 12–85 | Patients () | | Male | 7 (44%) | Female | 9 (56%) | Lesions () | | Peripheral | 19 (76%) | Central | 6 (24%) | Histology | | Leiomyosarcoma | 7 | Synovial cell | 5 | Osteosarcoma | 4 | Liposarcoma | 2 | NOS | 2 | Spindle cell | 1 | Chondrosarcoma | 1 | Liposarcoma | 1 | Hemangiopericytoma | 1 | Embryonal | 1 | Dose fractionation and BED* | | 54 Gy, 3 fractions (BED = 151.2 Gy) | 13 (52%) | 50 Gy, 4 fractions (BED = 112.5 Gy) | 9 (36%) | 36 Gy, 3 fractions (BED = 79.2 Gy) | 2 (8%) | 42 Gy, 3 fractions (BED = 100.8 Gy) | 1 (4%) |
|
|
Biological equivalent dose is calculated per (1), assuming / ratio of 10 for tumor ( = number of fractions, = total dose).
|